Lundbeck's position regarding misuse of Nembutal® CII Sodium Solution (pentobarbital sodium injection, USP) in the execution of prisoners

The company is opposed to the use of its products for the purpose of capital punishment. Use of our products to end lives contradicts everything we’re in business to do – provide therapies that help improve people’s lives.

Lundbeck makes pentobarbital available solely for its approved uses, one of which includes status epilepticus. This serious and life threatening emergency epilepsy causes approximately 42,000 deaths a year in the U.S. – a condition that can be helped with treatments such as pentobarbital. Clearly, use of this product to carry out the death penalty in US prisons falls outside its intended use.

We have vetted a broad range of remedies - many suggested during ongoing dialogue with external experts, government officials, and human rights advocates. After much consideration, we have determined that a restricted distribution system is the most meaningful means through which we can restrict the misuse of Nembutal. As such, the company announced on July 1, 2011 that Nembutal will be supplied exclusively through a specialty pharmacy drop ship program that will deny distribution of the product to prisons in U.S. states currently active in carrying out the death penalty by lethal injection. The company notified its distributors of the plan in late June.

The new distribution program ensures that hospitals and treatment centers will continue to have access to Nembutal for therapeutic purposes. Under the program, Lundbeck will review all Nembutal orders before providing clearance for shipping the product and deny orders from prisons located in states currently active in carrying out death penalty sentences.

Prior to receiving Nembutal, the purchaser must sign a form stating that the purchase of Nembutal is for its own use and that it will not redistribute any purchased product without express written authorization from Lundbeck. By signing the form, the purchaser agrees that the product will not be made available for use in capital punishment.

We will continue to urge states in the U.S. to refrain from using pentobarbital for the execution of prisoners as it contradicts everything we stand for as a company.
**Important Safety Information** NEMBUTAL is contraindicated in patients with a known hypersensitivity to any barbiturate, manifest or latent porphyria. Barbiturates including NEMBUTAL may be habit forming. Abrupt discontinuation may result in withdrawal symptoms, including delirium, convulsions and possibly death. Too rapid of an intravenous administration may cause respiratory depression, apnea, laryngospasm, or vasodilation with fall in blood pressure.

Concomitant use of alcohol or other CNS depressants may produce additive CNS depressant effects. Barbiturates should be administered with caution, if at all, to patients who are mentally depressed, have suicidal tendencies, chronic or acute pain. Barbiturates can cause fetal damage and infants may have withdrawal symptoms if mothers receive barbiturates. Withdrawal symptoms occur in infants born to mothers who receive barbiturates during the last trimester of pregnancy. Prolonged treatment with barbiturates should be monitored.

The most commonly reported adverse event (>1 in 100 patients) is somnolence.

For more information, please see Full Prescribing Information available at www.Lundbeckinc.com or www.LundbeckSHARE.com.